[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-detachment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-detachment":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,52,78,108,137,162,198,231,257,284,307,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":47,"leadSponsor":49,"locationsCount":4},"100642544","artificial-intelligence-assisted-lesion-based-urgent-referral-triage-of-ultra-widefield-retinal-images-100642544",false,"NCT07643129","Artificial Intelligence-Assisted Lesion-Based Urgent Referral Triage of Ultra-Widefield Retinal Images","Clinical Utility of an Artificial Intelligence-Assisted Lesion-Based Urgent Referral Triage System for Ultra-Widefield Retinal Images: A Prospective Multi-Reader Multi-Case Randomized Reader Study","ALERT-UWF","Inclusion Criteria:\n\n* Licensed ophthalmologists\n* Willing to participate as readers\n* Completion of study training\n\nExclusion Criteria:\n\n* Retinal specialists involved in establishing gold-standard labels\n* Prior access to gold-standard labels\n* Incomplete study participation",true,"ALL","18 Years",{"count":21,"type":22},8,"ESTIMATED","INTERVENTIONAL",[25],"NA","his study evaluates the clinical utility of an artificial intelligence (AI)-assisted lesion-based urgent referral triage system for ultra-widefield (UWF) retinal images.\n\nUnlike disease-classification systems, the AI system identifies predefined vision-threatening retinal findings and generates lesion-level urgent referral recommendations. Participating ophthalmologists will evaluate UWF retinal images under randomized AI-assisted and unassisted conditions.\n\nThe primary objective is to determine whether lesion-based AI assistance improves urgent referral triage performance compared with unaided image interpretation.",[28,29,30,31,32,33],"Vision-Threatening Retinal Lesions","Urgent Referral Retinal Findings","Retinal Detachment","Pre-retinal Hemorrhage","Subretinal Hemorrhage","Retinal Neovascularization",[35,36,37,38,39,40],"Artificial Intelligence","Urgent Referral","Lesion-Based Triage","Ultra-Widefield Imaging","Clinical Decision Support","Multi-Reader Multi-Case Study","NOT_YET_RECRUITING","2026-06-10",{"date":44,"type":45},"2026-06-15","ACTUAL",{"date":44,"type":22},{"date":48,"type":22},"2026-06-30",{"name":50,"class":51},"Xiamen Ophthalmology Center Affiliated to Xiamen University","OTHER",{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100631411","proteomic-biomarker-identification-in-age-related-macular-degeneration-diabetic-retinopathy-and-retinal-detachment-100631411","NCT07500324","Proteomic Biomarker Identification in Age-Related Macular Degeneration, Diabetic Retinopathy and Retinal Detachment","Identification And Validation Of Biomarkers In Ophthalmological Diseases (Age-Related Macular Degeneration, Diabetic Retinopathy And Retinal Detachment) Through Clinical Proteomic Approaches","PRO Project","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to understand the study procedures and provide written informed consent\n* Willingness and ability to comply with study procedures and visits\n\nFor case subjects:\n\n* Patients with age-related macular degeneration (intermediate or advanced, including geographic atrophy or neovascular AMD)\n* Patients with diabetic retinopathy (non-proliferative or proliferative, with or without diabetic macular edema)\n* Patients undergoing surgery for primary or recurrent retinal detachment\n\nFor control subjects:\n\n* Patients scheduled for cataract surgery with no documented retinal diseases (e.g., AMD, diabetic retinopathy, retinal vascular occlusions, or retinal epithelial disorders)\n* Outpatients with no documented retinal diseases\n* For retinal detachment subgroup: patients undergoing macular surgery (e.g., macular pucker or macular hole) or cataract surgery with attached retina\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Presence of infectious ocular diseases\n* Alterations in the electrophoretic profile of gamma globulins",{"count":61,"type":22},260,[25],"This prospective interventional translational study aims to identify and validate protein biomarkers associated with major ophthalmological diseases, including age-related macular degeneration, diabetic retinopathy (DR), and retinal detachment (RD). A total of approximately 260 participants (cases and controls) will be enrolled at a single center.\n\nBiological samples, including peripheral blood, tears, aqueous humor, vitreous humor, and subretinal fluid, will be collected during routine clinical and surgical procedures. Advanced clinical proteomics approaches will be applied to characterize molecular signatures associated with disease onset, progression, and response to treatment.\n\nThe study seeks to improve the understanding of disease pathophysiology and support the development of novel diagnostic and prognostic biomarkers in ophthalmology.",[65,66,30],"Age-Related Macular Degeneration (AMD)","Diabetic Retinopathy (DR)","RECRUITING","2026-05-29",{"date":70,"type":45},"2026-06-02",{"date":72,"type":45},"2024-01-24",{"date":74,"type":22},"2027-01",{"name":76,"class":51},"Fondazione G.B. Bietti, IRCCS",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":92,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100561267","phase-4-nicotinamide-riboside-oral-supplementation-in-macula-off-retinal-detachment-100561267","NCT06587945","Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","A Randomised Double-Masked Placebo-Controlled Trial of Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment","NOMAD","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Able to give informed consent and comply with all study visits and procedures.\n* Present within 10 days of macula-off retinal detachment (based on patient-reported history of loss of central vision)\n* Present to the hospital with a visual acuity of hand motion or better in the study eye\n* Have had previous cataract surgery in the study eye\n* Have clinical indication for standard retinal reattachment surgery by means of a pars plana vitrectomy and gas tamponade\n* In the opinion of the investigator, be able to safely undergo all study procedures.\n\nKey exclusion Criteria:\n\n* Any known significant ocular disease in the study eye (e.g., cornea opacity) which, in the opinion of the investigator, would preclude a visual acuity of at least 6\u002F7.5 (20\u002F25) following successful vitrectomy or limit adequate visibility of the retina.\n* Any other ocular pathology in the study eye requiring treatment with topical ophthalmic drops or intravitreal injection.\n* History of previous ocular surgery in the study eye other than uncomplicated cataract surgery with posterior chamber intraocular lens and intact posterior capsule or a refractive surgery (surgery must have occurred at least 3 months prior to the baseline visit).\n* Participation in other clinical trials or use of any other investigational drugs or devices within 3 months prior to study participation.\n* Females who are pregnant or lactating and women of childbearing potential.\n* Known retinopathy, known hepatic disease (or history of significant chronic liver disease), or known renal disease. Patients Participants with diabetes and no known retinopathy may be enrolled.\n* History of uncontrolled hypertension.\n* History of stroke, transient ischemic attack, or major cardiac surgery within 3 months prior to study, or current treatment for systemic infection.\n* Any ocular or systemic condition that in the opinion of the investigator could compromise the safety of the patientparticipant, or may interfere with the safety and tolerability assessments or study procedures of the trial.",{"count":87,"type":22},144,[89],"PHASE4","Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment. The 'macula' refers to the very centre of the retina, with the highest density of retinal cells, most responsible for vision. Significant vision loss occurs when this part of the retina becomes separated (termed a 'macula-off retinal detachment'). Typically, surgery is required to repair the retinal detachment.\n\nSupporting the health of retinal cells at the macula may prolong their survival after detachment and their recovery postoperatively. Recent evidence has shown that boosting our nicotinamide adenine dinucleotide (NAD+) levels may improve the health of these cells and prolong their survival if detached. Oral Nicotinamide Riboside (NR) is converted into NAD+, and while not studied for macula-off retinal detachments, has been safely used in a range of other conditions. This study is designed to help evaluate the safety and tolerability of NR to help preserve vision in people diagnosed with macula-off retinal detachment.\n\nThis study drug is given as an oral supplement (tablet) at the time of retinal detachment diagnosis, and daily for 20 weeks thereafter. The drug aims to prolong survival of cells in the retina (and macula) and their recovery after surgery.\n\nThe long-term goal of this treatment is to reduce loss of vision after retinal detachment. The researchers will compare NR to a placebo (a look-alike substance that contains no drug) to see if NR has a positive effect on photoreceptor survival and quality of vision postoperatively.\n\nNR has been approved by the Therapeutic Goods Administration in Australia for many purposes but has not been approved for use in retinal detachment treatment.",[30],[93,94,95,96,97],"Nicotinamide Riboside","Retinal detachment","Photoreceptors","Macula-off","Vitrectomy","2026-03-19",{"date":100,"type":45},"2026-03-23",{"date":102,"type":45},"2025-09-19",{"date":104,"type":22},"2028-03-30",{"name":106,"class":51},"Center for Eye Research Australia",5,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":77},"100610477","surgical-procedure-efficiency-evaluation-study-100610477","NCT07228091","Surgical Procedure Efficiency Evaluation stuDy","Surgical Procedure Efficiency Evaluation stuDy (SPEED): Combination Phaco-Vitrectomy Surgeries With UNITY VCS vs. Constellation in a Real-World Operating Room Setting","Key Inclusion Criteria:\n\n* Able to understand and sign an informed consent form (ICF) that has been approved by an ethics committee.\n* Planned combined phacovitrectomy procedure at one of the selected surgical sites.\n* Planned combined phacovitrectomy procedure with 25-gauge (G) vitrectomy tools.\n\nKey Exclusion Criteria:\n\n* Unplanned\u002Femergency phacovitrectomy.\n* Pregnant.\n* Past history of phacovitrectomy. cataract, vitrectomy in the planned operative eye.\n* Other protocol-defined exclusion criteria may apply.",{"count":116,"type":22},180,"OBSERVATIONAL","The purpose of this real-world evidence study is to compare surgical procedure times for UNITY® VCS and CONSTELLATION® Vision System.",[120,121,30,122,123],"Cataract","Vitreous Hemorrhage","Macular Pucker","Macular Holes",[125,126],"anterior segment ophthalmic surgery","posterior segment ophthalmic surgery","2026-02-12",{"date":129,"type":45},"2026-02-17",{"date":131,"type":45},"2026-02-09",{"date":133,"type":22},"2026-08",{"name":135,"class":136},"Alcon Research","INDUSTRY",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":77},"100620920","spring-loaded-syringe-for-active-silicon-oil-extraction-100620920","NCT07363889","Spring Loaded Syringe for Active Silicon Oil Extraction","Vitrectomy Machine Versus Spring Loaded Syringe for Active Silicon Oil Extraxtion","Inclusion Criteria:\n\n* Patients subjected previously to pars plana vitrectomy with silicon oil tamponade.\n\nExclusion Criteria:\n\n* Recurrent retinal detachment\n* Previous scleral buckling\n* Previous glaucoma surgery\n* Bleeding tendencies\n* Anterior staphyloma",{"count":145,"type":22},200,[25],"The aim of our study is to compare between two techniques used for active SOR. The outcomes include efficiency and safety.\n\nPatients with silicon filled eyes and prepared for SOR 540 eyes of 505 patients (one eye in 470 patients, and both eyes in 35 patients) were enrolled in the study.\n\nAll eyes underwent SOR using 23-Gauge PPV. The eyes were classified according to the surgical technique used for SOR into two groups:- Group A: SOR was performed using SO extraction program built in Optikon vitrectomy device Group B: SOR was performed using modified spring loaded syringe.",[30],[150,151,152],"Pars plana vitrectomy","Silicon oil tamponade","Silicon oil extraction","2026-01-14",{"date":155,"type":45},"2026-01-23",{"date":157,"type":45},"2022-01-04",{"date":159,"type":22},"2027-05",{"name":161,"class":51},"Sohag University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":77},"100372409","high-resolution-high-speed-multimodal-ophthalmic-imaging-100372409","NCT04129021","High Resolution, High-speed Multimodal Ophthalmic Imaging","High Resolution and High Speed Multimodal Ophthalmic Imaging","IMA-MODE","Inclusion Criteria:\n\n* People over 18\n* Patient with a pathology affecting the eye or healthy volunteer\n* Participant who signed the consent\n* Beneficiaries of the health insurance\n\nExclusion Criteria:\n\n* Patients with a history of photosensitivity.\n* Patients who have just received a photodynamic therapy treatment (\n* Patients taking drugs with photosensitivity as a side effect.\n* Persons with pacemakers or other implanted electronic medical device\n* Patients with viral conjunctivitis or any other infectious disease.\n* Patients with skin lesions on the neck or forehead\n* Patients at high risk of damage from optical radiation, such as aphakic patients, or patients with decreased sensitivity to light due to fundus disease.\n* Pregnant or lactating women\n* Participant unable to be followed throughout the study\n* Vulnerable people\n* Subjects with predisposition to closure of the iridocorneal angle",{"count":171,"type":22},1200,[25],"Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical imaging systems are limited in resolution, speed, or access to certain structures of the eye.\n\nThe use of a high-resolution imaging system improves the resolution of ophthalmoscopes by several orders of magnitude, allowing the visualization of many microstructures of the eye: photoreceptors, vessels, nerve bundles in the retina, cells and nerves in the cornea.\n\nThe use of a high-speed acquisition imaging system makes it possible to detect functional measurements such as the speed of blood flow. The combination of data from multiple imaging systems to obtain multimodal information is of great importance for improving the understanding of structural changes in the eye during a disease.\n\nThe purpose of this project is to observe structures that are not detectable with routinely used systems.",[175,176,177,178,30,179,180,181,182,183,184,185,186,187,188],"Retinitis Pigmentosa","Maculopathy, Age Related","Macular Dystrophy","Macular Edema","Retinal Degeneration","Glaucoma","Vascular Inflammation","Hypertension","Stroke","Diabetes","Corneal Dystrophy","Keratoconus","Dry Eye","Trauma","2025-11-17",{"date":191,"type":45},"2025-11-18",{"date":193,"type":45},"2019-07-03",{"date":195,"type":22},"2027-07",{"name":197,"class":51},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":17,"sex":18,"minAge":206,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":209,"conditions":210,"keywords":218,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":77},"100340496","intraoperative-oct-guidance-of-intraocular-surgery-ii-100340496","NCT03713268","Intraoperative OCT Guidance of Intraocular Surgery II","Intraoperative OCT Guidance of Intraocular Surger","MIOCT","Inclusion Criteria:\n\n1. Healthy controls: Healthy eyes without known disease: refractive error including myopia and non-significant cataract is allowed. For selected testing pseudophakia is allowed.\n2. Surgeons as research subjects: Adult (≥18 years old)\n3. Surgical patients (vitreoretinal surgery): Patients undergoing examination under anesthesia or surgery for vitreoretinal diseases\n4. Surgical patients (anterior segment surgery-glaucoma, ocular surface or strabismus requiring extraocular muscle surgery): Include both adults and children. Patient undergoing primary, elective minimally invasive glaucoma surgery, ocular surface surgery, or strabismus surgery.\n\nExclusion Criteria:\n\n1. Healthy controls: Any ocular disease that restricts the ability to perform OCT scanning. Conflict of interest with investigators\u002Fstudy personnel, e.g. a student in the lab of an investigator.\n2. Surgeons as research subjects: no specific exclusion criteria.\n3. Surgical patients (vitreoretinal surgery): Neonates (\\\u003C 4 weeks of age) and patients with any ocular disease that restricts the ability to perform OCT scanning.\n4. Surgical patients (anterior segment surgery-corneal and cataract diseases): Pediatric patients: The cornea and cataract surgery studies will be restricted to adults (≥ 18 years). Children do not have cataract surgery typically by residents and therefore would not fit our study design. Similarly pediatric corneal transplants are very rare.","4 Weeks",{"count":208,"type":22},262,"The overall five-year goals of the project are to develop novel technology to provide actionable new information through provision of live volumetric imaging during surgery, improving surgical practice and outcomes. The investigators believe this technology will enable novel ophthalmic and other microsurgeries not possible due to current limitations in surgical visualization.",[123,211,212,30,213,214,120,215,216,217],"Epiretinal Membrane","Diabetic Retinopathy","Retinal Disease","Preretinal Fibrosis","Ocular Tumor","Strabismus","Healthy",[219,204,220,221],"Microscope Integrated optical coherence tomography","OCT Angiography","OCTA","2025-10-02",{"date":224,"type":45},"2025-10-06",{"date":226,"type":45},"2018-09-30",{"date":228,"type":22},"2027-05-31",{"name":230,"class":51},"Duke University",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":243,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":77},"100607107","animated-video-education-for-retinal-surgery-100607107","NCT07184255","Animated Video Education for Retinal Surgery","Multilingual Animated Video Education for Retinal Detachment Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥18 years.\n* Diagnosis of primary rhegmatogenous retinal detachment.\n* Planned repair with pneumatic retinopexy (PnR), pars plana vitrectomy (PPV), or scleral buckle (SB).\n* Able to provide informed consent.\n* Preferred language available among study videos.\n\nExclusion Criteria:\n\n* Repeat retinal detachment surgery in study eye.\n* Combined complex procedures (e.g., PPV + corneal transplant).\n* Severe cognitive impairment precluding consent.\n* Hearing impairment preventing use of audio track (without aid).",{"count":239,"type":22},600,[25],"Retinal detachment is a vision-threatening condition that requires urgent surgical repair. Understanding the condition, the surgery, and post-operative instructions is difficult for many patients, particularly in multilingual and multicultural populations. This study will evaluate whether short, animated educational videos, available in 25 languages and designed with accessibility features for patients with low vision, improve patient knowledge, reduce anxiety, and support adherence to post-operative instructions when added to standard counselling. Patients will be randomized to standard counselling alone versus counselling plus video in their preferred language. Outcomes will be measured with validated questionnaires at baseline, immediately after counselling, and one week post-surgery.",[30],[30,244,245,246,247,248],"Patient Education","Multilingual Video Intervention","Health Literacy","Eye surgery","Knowledge translation","2025-09-13",{"date":102,"type":45},{"date":252,"type":22},"2026-01-01",{"date":254,"type":22},"2026-12-31",{"name":256,"class":51},"University of Toronto",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":267,"conditions":268,"keywords":272,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":77},"100241590","discover-study-microscope-integrated-intraoperative-oct-study-100241590","NCT02423213","DISCOVER Study: Microscope-integrated Intraoperative OCT Study","Determination of Feasibility of Intraoperative Spectral Domain Microscope Combined\u002FIntegrated OCT Visualization During En Face Retinal and Ophthalmic Surgery: DISCOVER Study","DISCOVER","Inclusion Criteria:\n\n* The study population includes any patient requiring ophthalmic surgery\n\nExclusion Criteria:\n\n* Under the age of 18 years.\n* Cognitive\u002FMentally impaired or unable to provide consent",{"count":266,"type":22},3000,"Optical coherence tomography (OCT )provides high resolution information regarding the anatomic structure of the tissues of the eye in a cross-sectional and 3 dimensional view. Much of this information is not able to be visualized by a clinician. Utilizing this information during surgery will allow for the ophthalmic surgeons to better understand how surgical procedures impact the anatomic structure of the eye.\n\nIn this study an OCT device that has been built into the microscope (rather than mounted on the side or held in the surgeon's hand) and will be utilized to take images at various milestones during surgery to assess feasibility and potential utility of this technology. Since it is built into the microscope, there are potential significant advantages over a separate system including increased efficiency, improved working distance, and the ability to visualize tissue-instrument interactions.",[269,270,271,211,30],"Retinal Diseases","Fuchs Endothelial Dystrophy","Macular Hole",[273,274,275],"OCT","image-guided surgery","ophthalmic surgery","2025-06-23",{"date":278,"type":45},"2025-06-26",{"date":280,"type":4},"2014-01",{"date":74,"type":22},{"name":283,"class":51},"The Cleveland Clinic",{"id":285,"slug":286,"hasResults":11,"nctId":287,"briefTitle":288,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":23,"phases":293,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":306},"100538746","phase-3-ursodeoxycholic-acid-udca-as-a-neuroprotective-adjuvant-treatment-to-rhegmatogenous-retinal-detachment-surgery-100538746","NCT06294847","Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery","UDCA","Inclusion Criteria:\n\n1. Aged 18 years or older,\n2. Scheduled to undergo surgical intervention through vitrectomy,\n3. Aphakic or pseudophakic patients,\n4. Experiencing rhegmatogenous retinal detachment affecting 2 quadrants or more,\n5. Presenting with macula OFF (raised macula) for 7 days or less before the onset of symptoms,\n6. Has signed a consent form,\n7. Affiliated with a health insurance plan.\n\nExclusion Criteria:\n\n1. Patients who have previously undergone vitrectomy for retinal detachment,\n2. Patients with vitreous hemorrhage or any other associated retinal pathologies,\n3. Monophthalmic patients,\n4. Women of childbearing age without effective contraceptive methods,\n5. Pregnant or lactating women,\n6. Hypersensitivity to the active substance, bile acids, or any of the excipients in Ursolvan® (see §6.1.1 of this protocol),\n7. Patients with peptic ulcers, acute or chronic liver disease, acute infection or inflammation of the gallbladder or bile ducts, recurrent gallstones, or obstruction of the bile ducts (common bile duct or cystic duct obstruction),\n8. Patients with radiopaque calcified gallstones,\n9. Patients with severe pancreatic disorders,\n10. Patients with Crohn's disease, ulcerative colitis, or other intestinal diseases that may alter the enterohepatic circulation of bile acids,\n11. Patients on oral treatment with cholestyramine, colestipol, antacids containing aluminum or magnesium hydroxide and\u002For smectite (aluminum oxide), cyclosporine, ciprofloxacin, nitrendipine, or dapsone,\n12. Patients with galactose intolerance, Lapp lactase deficiency, or glucose and galactose malabsorption syndrome (rare hereditary diseases),\n13. Patients participating or in the exclusion period following an interventional research with the use of prohibited medications in this study,\n14. Patients under protective custody.",{"count":292,"type":22},120,[294],"PHASE3","This study is indicated for patients with extended rhegmatogenous retinal detachment (RRD) (≥ 2 quadrants) with macula OFF lasting 7 days or less, pseudophakic or aphakic, and scheduled to undergo surgical intervention with vitrectomy and gas tamponade in one of the ophthalmology departments participating in the study.\n\nThe main objective is to assess the effectiveness of UDCA in visual acuity recovery at 3 months (i.e., the difference between preoperative visual acuity and visual acuity 3 months after surgery) in pseudophakic or aphakic patients who have undergone successful surgical intervention (reattachment of the retina) through vitrectomy and gas tamponade following rhegmatogenous retinal detachment (RRD).\n\n120 patients will be enrolled and randomized in two groups:\n\n* the experimental arm \"UDCA Group,\" with oral administration of ursodeoxycholic acid (Ursolvan®)\n* the control group \"Placebo Group,\" with oral administration of the placebo.",[30],"2025-05-12",{"date":299,"type":45},"2025-05-14",{"date":301,"type":45},"2024-08-20",{"date":303,"type":22},"2027-11",{"name":305,"class":51},"Hopital Foch",2,{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":317,"briefSummary":318,"conditions":319,"keywords":320,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":77},"100505586","retinal-detachment-outcomes-study-100505586","NCT05863312","REtinal Detachment Outcomes Study","Rhegmatogenous rEtinal Detachment With or withOut Scleral Buckle (REDOS) Trial: a Factorial, Randomized Controlled Trial","REDOS","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of rhegmatogenous retinal detachment\n\nExclusion Criteria, retinal detachment with:\n\n* Proliferative vitreoretinopathy (PVR) grade ≥C2\n* Chronic RRD with duration \\>3 months\n* Proliferative diabetic retinopathy with tractional retinal detachment (RD)\n* Macular holes\n* Epiretinal membrane grade 3 or 4\n* Traumatic RD\n* Giant retinal tears\n* Retinal dialysis\n* Foveoschisis\n* Wet age-related macular degeneration\n* Endophthalmitis\n* Acute retinal necrosis\n* Coats disease\n* Retinopathy of prematurity\n* Retinoschisis\n* Retinal colobomas\n* Prior glaucoma surgery or strabismus surgery (favoring PPV only)\n* Superior RD extent less than 3 clock hours (favoring PPV only)",{"count":316,"type":22},560,[25],"Background: Few large randomized controlled trials provide strong evidence to guide surgical repair of primary rhegmatogenous retinal detachment (RRD) repair. The purpose of this factorial, single-blind, randomized controlled trial is to analyze and compare the surgical outcomes, functional visual outcomes, complications, and quality of life associated with RRD repair using (A) pars plana vitrectomy only (PPV) or PPV with scleral buckle (PPV-SB) and (B) sulfur hexafluoride gas (SF6) or perfluoropropane gas (C3F8) tamponade.\n\nMethods: Eligible patients with moderately complex RRD will be randomized 1:1 to PPV or PPV-SB and 1:1 to SF6 or C3F8 gas tamponade. Approximately 560 patients will be recruited to be able to detect a difference of around 10% in SSAS rate between groups. Patients will be followed using multimodal imaging and quality of life questionnaires before and after the surgical repair until 1 year postoperative. The primary outcome will be single surgery anatomic success (SSAS), defined as absence of reoperation for recurrent RRD in the operating room. Secondary outcomes will be pinhole visual acuity (PHVA) at 8-10 weeks and 6 months, final best-corrected visual acuity (BCVA), final retina status (i.e., attached or detached), time to onset of RRD recurrence, severity and number of complications, and questionnaire results.\n\nDiscussion: This will be the first 2 × 2 factorial randomized controlled trial examining repair techniques in primary RRD. It will also be the first randomized controlled trial to compare gas tamponade between the two most common agents. Notably, it will be adequately powered to detect a clinically significant effect size. The use of multimodal imaging will also be a novel aspect of this study, allowing us to compare head-to-head the impact of adding an SB to the retina's recovery after RRD repair and of differing gas tamponades. Until now, the treatment of RRD has been largely guided by pragmatic retrospective cohort studies. There is a lack of strong evidence guiding therapeutic decisions and this trial will address (1) whether supplemental SB is justified and (2) whether longer duration gas tamponade with C3F8 is necessary.",[30],[150,321,322,323,324,325,326,327,328,329],"Scleral buckle","Rhegmatogenous retinal detachment","Proliferative vitreoretinopathy","Anatomic success","Visual acuity","Retinal displacement","Postoperative pain","Quality of life","Complications","2023-11-17",{"date":332,"type":45},"2023-11-18",{"date":334,"type":45},"2023-09-26",{"date":336,"type":22},"2028-07",{"name":338,"class":51},"CHU de Quebec-Universite Laval",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":23,"phases":349,"briefSummary":350,"conditions":351,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100480605","internal-limiting-membrane-peeling-in-retinal-detachment-surgery-100480605","NCT05538156","Internal Limiting Membrane Peeling in Retinal Detachment Surgery","Internal Limiting Membrane Peeling in Macula-off Retinal Detachment With Grade B Proliferative Vitreoretinopathy","IMPURITY","Inclusion Criteria:\n\n* Patients older than 18 years old\n* With macula-off retinal detachment complicated by grade B proliferative vitreoretinopathy\n\nExclusion Criteria:\n\n* Underage patients\n* History of retinal detachment\n* History of intraocular surgery (except for cataract surgery)\n* Traumatic retinal detachment\n* Macular hole-associated retinal detachment\n* Concurrent macular disease (diabetic maculopathy, age-related macular degeneration)",{"count":348,"type":22},126,[25],"Despite advances in surgical techniques over the recent decades, proliferative vitreoretinopathy (PVR) remains the main obstacle to successful rhegmatogenous retinal detachment (RRD) repair, accounting for nearly 75% of all primary surgical failures. It is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both surfaces of the detached retina as well as intraretinal fibrosis.\n\nThe Retina Society classification, modified in 1991 and currently the most widely used, divided PVR into three grades. Grade A is limited to the presence of vitreous haze and pigment clumps. Grade B includes rolled or irregular edges of tear and\u002For inner retinal surface wrinkling with possible retinal stiffness and vessel tortuosity. Grade C is defined as the presence of full-thickness fixed retinal folds and is further subdivided based on the number of hours involved and the location.\n\nRecently, Foveau et al., in a retrospective comparative case series, have demonstrated that performing internal limiting membrane (ILM) peeling during RRD surgery may increase the anatomical success rate for this indication.\n\nThe aim of this multi-center, prospective, randomized controlled clinical trial study is to evaluate the effectiveness of ILM peeling on surgical outcomes in patients with primary macula-off RRD complicated by grade B PVR.",[30,352],"Proliferative Vitreoretinopathy","2022-09-09",{"date":355,"type":45},"2022-09-13",{"date":357,"type":22},"2022-09",{"date":359,"type":22},"2027-12",{"name":361,"class":51},"Central Hospital, Nancy, France"]